Piet de Witte1, Christien A de Witt2, Johan L van de Minkelis3, Djamila Boerma4, H Frank Solinger5, C Erik Hack6,7,8, Peter Bruins1. 1. Department of Anesthesiology, Intensive Care & Pain Management, St Antonius Ziekenhuis, Nieuwegein, The Netherlands. 2. Department of Anesthesiology & Pain Management, Medisch Centrum, Alkmaar, The Netherlands. 3. Department of Anesthesiology & Pain Management, Elisabeth-TweeSteden ziekenhuis, Tilburg, The Netherlands. 4. Department of Surgery, St Antonius Ziekenhuis, Nieuwegein, The Netherlands. 5. Department of Extracorporeal Circulation, St Antonius Ziekenhuis, Nieuwegein, The Netherlands. 6. Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. 7. Department of Rheumatology, University Medical Center Utrecht, Utrecht, The Netherlands. 8. Department of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND: Surgical cytoreduction and simultaneous hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis has a high incidence of postoperative complications. Inadequate intraoperative volume therapy is a known risk factor for the development of postoperative complications. Another possible risk factor is the inflammatory response due to surgery and HIPEC. The aim of this observational pilot study was to monitor fluid intake in the first 24 hours peri- and postoperative by using a non-invasive cardiac output indicator. Furthermore, we measured circulating cytokines and evaluated the possible relation of these changes of inflammatory response with the non-invasive monitored fluid management. METHODS: Twenty-four patients undergoing cytoreductive surgery and HIPEC for peritoneal carcinomatosis were included. Patients were randomised into either a liberal fluid management group using intra-arterial blood pressure and central venous pressure measurement or a restrictive group by using intra-arterial blood pressure and central venous pressure measurement with FloTrac/Vigileo monitoring. Cytokines were measured with multiplex immunoassays. RESULTS: We found no difference in the amount of fluid administration in patients undergoing HIPEC surgery with FloTrac/Vigileo monitoring compared to standard care. Furthermore, there was no difference in mortality, ICU and hospital length of stay between both groups. A severe inflammatory response was seen in all patients after the HIPEC procedure with a rapid increase of interleukins and C-reactive protein (CRP). There was however no difference between our intervention and control group in the severity of this reaction. Finally, we found no relation between the severity of the inflammatory response and mortality, or a composite end-point of mortality and severe complications within 30 days postoperative. CONCLUSIONS: FloTrac/Vigileo monitoring does not lead to a more restrictive fluid administration and does not influence short-term clinical course in patients undergoing HIPEC surgery. The procedure itself leads to a severe inflammatory response, which is not affected by the use of FloTrac/Vigileo. Our data do not support the use of FloTrac/Vigileo monitoring in patients undergoing HIPEC surgery concerning fluid restrictive management.
BACKGROUND: Surgical cytoreduction and simultaneous hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis has a high incidence of postoperative complications. Inadequate intraoperative volume therapy is a known risk factor for the development of postoperative complications. Another possible risk factor is the inflammatory response due to surgery and HIPEC. The aim of this observational pilot study was to monitor fluid intake in the first 24 hours peri- and postoperative by using a non-invasive cardiac output indicator. Furthermore, we measured circulating cytokines and evaluated the possible relation of these changes of inflammatory response with the non-invasive monitored fluid management. METHODS: Twenty-four patients undergoing cytoreductive surgery and HIPEC for peritoneal carcinomatosis were included. Patients were randomised into either a liberal fluid management group using intra-arterial blood pressure and central venous pressure measurement or a restrictive group by using intra-arterial blood pressure and central venous pressure measurement with FloTrac/Vigileo monitoring. Cytokines were measured with multiplex immunoassays. RESULTS: We found no difference in the amount of fluid administration in patients undergoing HIPEC surgery with FloTrac/Vigileo monitoring compared to standard care. Furthermore, there was no difference in mortality, ICU and hospital length of stay between both groups. A severe inflammatory response was seen in all patients after the HIPEC procedure with a rapid increase of interleukins and C-reactive protein (CRP). There was however no difference between our intervention and control group in the severity of this reaction. Finally, we found no relation between the severity of the inflammatory response and mortality, or a composite end-point of mortality and severe complications within 30 days postoperative. CONCLUSIONS: FloTrac/Vigileo monitoring does not lead to a more restrictive fluid administration and does not influence short-term clinical course in patients undergoing HIPEC surgery. The procedure itself leads to a severe inflammatory response, which is not affected by the use of FloTrac/Vigileo. Our data do not support the use of FloTrac/Vigileo monitoring in patients undergoing HIPEC surgery concerning fluid restrictive management.
Authors: Birgitte Brandstrup; Hanne Tønnesen; Randi Beier-Holgersen; Else Hjortsø; Helle Ørding; Karen Lindorff-Larsen; Morten S Rasmussen; Charlotte Lanng; Lene Wallin; Lene H Iversen; Christina S Gramkow; Mette Okholm; Tine Blemmer; Poul-Erik Svendsen; Henrik H Rottensten; Birgit Thage; Jens Riis; Inge S Jeppesen; Dorthe Teilum; Anne Mette Christensen; Ben Graungaard; Frank Pott Journal: Ann Surg Date: 2003-11 Impact factor: 12.969
Authors: Vitomir I Rankovic; Vesna P Masirevic; Maja J Pavlov; Miljan S Ceranic; Marija G Milenkovic; Aleksandar P Simic; Dragutin M Kecmanovic Journal: Hepatogastroenterology Date: 2007-03
Authors: Tomasz Jaroslaw Szczesny; Robert Slotwinski; Aleksander Stankiewicz; Bruno Szczygiel; Marzanna Zaleska; Maria Kopacz Journal: Eur J Cardiothorac Surg Date: 2007-02-20 Impact factor: 4.191
Authors: Yasser Sakr; Jean-Louis Vincent; Konrad Reinhart; Didier Payen; Christian J Wiedermann; Durk F Zandstra; Charles L Sprung Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: Tong J Gan; Andrew Soppitt; Mohamed Maroof; Habib el-Moalem; Kerri M Robertson; Eugene Moretti; Peter Dwane; Peter S A Glass Journal: Anesthesiology Date: 2002-10 Impact factor: 7.892
Authors: J H Nuijens; J J Abbink; Y T Wachtfogel; R W Colman; A J Eerenberg; D Dors; A J Kamp; R J Strack van Schijndel; L G Thijs; C E Hack Journal: J Lab Clin Med Date: 1992-02
Authors: Michael Flood; Vignesh Narasimhan; Kasmira Wilson; Wei Mou Lim; Robert Ramsay; Michael Michael; Alexander Heriot Journal: Ann Surg Oncol Date: 2021-10-01 Impact factor: 5.344